{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:43:47Z","timestamp":1776779027895,"version":"3.51.2"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Digit. Med."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mobility is an important correlate of physical, cognitive, and mental health in chronic illness, and can be measured passively with mobile phone global positional satellite (GPS) sensors. To date, GPS data have been reported in a few studies of schizophrenia, yet it is unclear whether these data correlate with concurrent momentary reports of location, vary by people with schizophrenia and healthy comparison subjects, or associate with symptom clusters in schizophrenia. A total of 142 participants with schizophrenia (<jats:italic>n<\/jats:italic>\u2009=\u200986) or healthy comparison subjects (<jats:italic>n<\/jats:italic>\u2009=\u200956) completed 7 days of ecological momentary assessment (EMA) reports of location and behavior, and simultaneous GPS locations were tracked every five minutes. We found that GPS-derived indicators of average distance travelled overall and distance from home, as well as percent of GPS samples at home were highly correlated with EMA reports of location at the day- and week-averaged level. GPS-based mobility indicators were lower in schizophrenia with medium to large effect sizes. Less GPS mobility was related to greater negative symptom severity, particularly diminished motivation, whereas greater GPS mobility was weakly associated with more community functioning. Neurocognition, depression, and positive symptoms were not associated with mobility indicators. Therefore, passive GPS sensing could provide a low-burden proxy measure of important outcomes in schizophrenia, including negative symptoms and possibly of functioning. As such, passive GPS sensing could be used for monitoring and timely interventions for negative symptoms in young persons at high risk for schizophrenia.<\/jats:p>","DOI":"10.1038\/s41746-019-0182-1","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T14:48:06Z","timestamp":1573224486000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":101,"title":["GPS mobility as a digital biomarker of negative symptoms in schizophrenia: a case control study"],"prefix":"10.1038","volume":"2","author":[{"given":"Colin A.","family":"Depp","sequence":"first","affiliation":[]},{"given":"Jesse","family":"Bashem","sequence":"additional","affiliation":[]},{"given":"Raeanne C.","family":"Moore","sequence":"additional","affiliation":[]},{"given":"Jason L.","family":"Holden","sequence":"additional","affiliation":[]},{"given":"Tanya","family":"Mikhael","sequence":"additional","affiliation":[]},{"given":"Joel","family":"Swendsen","sequence":"additional","affiliation":[]},{"given":"Philip D.","family":"Harvey","sequence":"additional","affiliation":[]},{"given":"Eric L.","family":"Granholm","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,11,8]]},"reference":[{"key":"182_CR1","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/schbul\/sbv018","volume":"41","author":"MF Green","year":"2015","unstructured":"Green, M. F., Llerena, K. & Kern, R. S. The \u201cRight Stuff\u201d Revisited: what have we learned about the determinants of daily functioning in schizophrenia? Schizophrenia Bull. 41, 781\u2013785 (2015).","journal-title":"Schizophrenia Bull."},{"key":"182_CR2","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.schres.2013.01.005","volume":"145","author":"E Granholm","year":"2013","unstructured":"Granholm, E., Ben-Zeev, D., Fulford, D. & Swendsen, J. Ecological momentary assessment of social functioning in schizophrenia: impact of performance appraisals and affect on social interactions. Schizophrenia Res. 145, 120\u2013124 (2013). 02\/10.","journal-title":"Schizophrenia Res."},{"key":"182_CR3","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1017\/S0033291708004947","volume":"39","author":"I Myin-Germeys","year":"2009","unstructured":"Myin-Germeys, I. et al. Experience sampling research in psychopathology: opening the black box of daily life. Psychol. Med. 39 1533\u20131547 (2009).","journal-title":"Psychol. Med."},{"key":"182_CR4","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1017\/S0033291717001295","volume":"47","author":"M Schneider","year":"2017","unstructured":"Schneider, M., Reininghaus, U., van Nierop, M., Janssens, M. & Myin-Germeys, I. Does the Social Functioning Scale reflect real-life social functioning? An experience sampling study in patients with a non-affective psychotic disorder and healthy control individuals. Psychol. Med. 47, 2777\u20132786 (2017).","journal-title":"Psychol. Med."},{"key":"182_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.euroneuro.2015.08.008","volume":"25","author":"FM Bos","year":"2015","unstructured":"Bos, F. M. & Schoevers, R. A., . & aan het Rot, M. Experience sampling and ecological momentary assessment studies in psychopharmacology: a systematic review. Eur. Neuropsychopharmacol. 25, 1853\u20131864 (2015).2015\/11\/01\/.","journal-title":"Eur. Neuropsychopharmacol."},{"key":"182_CR6","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1146\/annurev-publhealth-040617-013731","volume":"39","author":"B Chaix","year":"2018","unstructured":"Chaix, B. Mobile sensing in environmental health and neighborhood research. Annu. Rev. Public Health 39, 367\u2013384 (2018).","journal-title":"Annu. Rev. Public Health"},{"key":"182_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023468","volume":"8","author":"H Britto","year":"2018","unstructured":"Britto, H., Oliveira, B. S., Gomes, C. S., Pinto, J. M. & Guerra, R. O. Contextual factors associated with life-space mobility in community-dwelling older adults based on International Classification of Functioning, Disability and Health: protocol for a systematic review. BMJ Open 8, e023468 (2018).","journal-title":"BMJ Open"},{"key":"182_CR8","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1046\/j.1532-5415.2003.51512.x","volume":"51","author":"PS Baker","year":"2003","unstructured":"Baker, P. S., Bodner, E. V. & Allman, R. M. Measuring life\u2010space mobility in community\u2010dwelling older adults. J. Am. Geriatrics Soc. 51, 1610\u20131614 (2003).","journal-title":"J. Am. Geriatrics Soc."},{"key":"182_CR9","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1159\/000355669","volume":"60","author":"JY Tung","year":"2014","unstructured":"Tung, J. Y. et al. Measuring life space in older adults with mild-to-moderate Alzheimer\u2019s disease using mobile phone GPS. Gerontology 60, 154\u2013162 (2014).","journal-title":"Gerontology"},{"key":"182_CR10","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10433-017-0434-3","volume":"15","author":"E Giannouli","year":"2018","unstructured":"Giannouli, E., Bock, O. & Zijlstra, W. Cognitive functioning is more closely related to real-life mobility than to laboratory-based mobility parameters. Eur. J. Ageing 15, 57\u201365 (2018).","journal-title":"Eur. J. Ageing"},{"key":"182_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1177\/0733464813512897","volume":"34","author":"M Wettstein","year":"2015","unstructured":"Wettstein, M. et al. Identifying mobility types in cognitively heterogeneous older adults based on GPS-tracking: what discriminates best? J. Appl. Gerontol. 34, 1001\u20131027 (2015).","journal-title":"J. Appl. Gerontol."},{"key":"182_CR12","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1155\/2016\/3261567","volume":"2016","author":"E Giannouli","year":"2016","unstructured":"Giannouli, E., Bock, O., Mellone, S. & Zijlstra, W. Mobility in old age: capacity is not performance. BioMed. Res. Int. 2016, 8 (2016).","journal-title":"BioMed. Res. Int."},{"key":"182_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/1359105316666654","volume":"23","author":"P Patel","year":"2018","unstructured":"Patel, P., Frederick, T. & Kidd, S. A. Physical health, community participation and schizophrenia. J. Health Psychol. 23, 79\u201383 (2018).","journal-title":"J. Health Psychol."},{"key":"182_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.jpsychires.2017.07.011","volume":"94","author":"M Strassnig","year":"2017","unstructured":"Strassnig, M. et al. Health status and mobility limitations are associated with residential and employment status in schizophrenia and bipolar disorder. J. Psychiatr. Res. 94, 180\u2013185 (2017).","journal-title":"J. Psychiatr. Res."},{"key":"182_CR15","doi-asserted-by":"crossref","unstructured":"Difrancesco, S. et al. Out-of-home activity recognition from GPS data in schizophrenic patients. Paper presented at 2016 IEEE 29th International Symposium on Computer-Based Medical Systems (CBMS) (2016).","DOI":"10.1109\/CBMS.2016.54"},{"issue":"8","key":"182_CR16","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1038\/s41386-018-0030-z","volume":"43","author":"Ian Barnett","year":"2018","unstructured":"Barnett, I. et al. Relapse prediction in schizophrenia through digital phenotyping: a pilot study. Neuropsychopharmacology 43, 1660\u20131666 (2018).","journal-title":"Neuropsychopharmacology"},{"key":"182_CR17","doi-asserted-by":"crossref","unstructured":"Wang, R. et al. CrossCheck: toward passive sensing and detection of mental health changes in people with schizophrenia. Paper presented at: Proceedings of the 2016 ACM International Joint Conference on Pervasive and Ubiquitous Computing (2016).","DOI":"10.1145\/2971648.2971740"},{"key":"182_CR18","doi-asserted-by":"crossref","unstructured":"Brusilovskiy, E., Klein, L. A. & Salzer M. S. Using global positioning systems to study health-related mobility and participation. Soc. Sci. Med. 161,134\u2013142 (2016).","DOI":"10.1016\/j.socscimed.2016.06.001"},{"key":"182_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/schbul\/sbv132","volume":"42","author":"J Firth","year":"2015","unstructured":"Firth, J. et al. Mobile phone ownership and endorsement of \u201cmHealth\u201d among people with psychosis: a meta-analysis of cross-sectional studies. Schizophrenia Bull. 42, 448\u2013455 (2015).","journal-title":"Schizophrenia Bull."},{"key":"182_CR20","doi-asserted-by":"crossref","unstructured":"Marshall, M. & Rathbone, J. Early intervention for psychosis. Cochr Database Syst Rev. 2011, CD004718-6.","DOI":"10.1002\/14651858.CD004718.pub3"},{"key":"182_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.eurpsy.2013.02.003","volume":"29","author":"J Lyne","year":"2014","unstructured":"Lyne, J. et al. Do psychosis prodrome onset negative symptoms predict first presentation negative symptoms? Eur. Psychiatry 29, 153\u2013159 (2014). 2014\/03\/01\/.","journal-title":"Eur. Psychiatry"},{"key":"182_CR22","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.psychres.2012.02.018","volume":"196","author":"D Piskulic","year":"2012","unstructured":"Piskulic, D. et al. Negative symptoms in individuals at clinical high risk of psychosis. Psychiatry Res. 196, 220\u2013224 (2012). 2012\/04\/30\/.","journal-title":"Psychiatry Res."},{"key":"182_CR23","unstructured":"Center, P. R. Demographics of Mobile Device Ownership and Adoption in the United States, https:\/\/www.pewinternet.org\/fact-sheet\/mobile\/ (2018)."},{"key":"182_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/archgenpsychiatry.2007.3","volume":"65","author":"TD Cannon","year":"2008","unstructured":"Cannon, T. D. et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch. Gen. Psychiatry 65, 28\u201337 (2008).","journal-title":"Arch. Gen. Psychiatry"},{"key":"182_CR25","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1093\/geronb\/gbx063","volume":"72","author":"E York Cornwell","year":"2017","unstructured":"York Cornwell, E. & Cagney, K. A. Aging in activity space: results from smartphone-based GPS-tracking of urban seniors. J. Gerontol. 72, 864\u2013875 (2017).","journal-title":"J. Gerontol."},{"key":"182_CR26","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.dhjo.2014.12.002","volume":"8","author":"NM Gell","year":"2015","unstructured":"Gell, N. M., Rosenberg, D. E., Carlson, J., Kerr, J. & Belza, B. Built environment attributes related to GPS measured active trips in mid-life and older adults with mobility disabilities. Disabil. Health J. 8, 290\u2013295 (2015).","journal-title":"Disabil. Health J."},{"key":"182_CR27","doi-asserted-by":"crossref","unstructured":"Granholm, E. et al. What do people with schizophrenia do all day? Ecological momentary assessment of real-world functioning in schizophrenia. Schizophrenia Bull. 31504955 (2019).","DOI":"10.1093\/schbul\/sbz070"},{"key":"182_CR28","unstructured":"First, M. B. et al. Structured clinical interview for DSM-IV-TR axis I disorders. Clinical Trials Version (SCID-CT). (Biometrics Research, New York State Psychiatric Institute, New York, 2007)."},{"key":"182_CR29","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1093\/oxfordjournals.schbul.a033483","volume":"26","author":"CJ Wallace","year":"2000","unstructured":"Wallace, C. J., Liberman, R. P., Tauber, R. & Wallace, J. The independent living skills survey: a comprehensive measure of the community functioning of severely and persistently mentally ill individuals. Schizophrenia Bull. 26, 631\u2013658 (2000).","journal-title":"Schizophrenia Bull."},{"key":"182_CR30","doi-asserted-by":"crossref","unstructured":"Schneider, L. C. & Struening, E. L. SLOF: a behavioral rating scale for assessing the mentally ill. Paper presented at: Social Work Research and Abstracts (1983).","DOI":"10.1093\/swra\/19.3.9"},{"key":"182_CR31","volume-title":"MATRICS Consensus Cognitive Battery Manual.","author":"KH Nuechterlein","year":"2006","unstructured":"Nuechterlein, K. H. & Green, M. F. MATRICS Consensus Cognitive Battery Manual. (MATRICS Assessment Inc., Los Angeles, CA, 2006)."},{"key":"182_CR32","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1192\/S0007125000291496","volume":"155","author":"N Andreason","year":"1989","unstructured":"Andreason, N. The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations. Br. J. Psychiatry 155, 49\u201352 (1989).","journal-title":"Br. J. Psychiatry"},{"key":"182_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1176\/appi.ajp.2012.12010109","volume":"170","author":"AM Kring","year":"2013","unstructured":"Kring, A. M., Gur, R. E., Blanchard, J. J., Horan, W. P. & Reise, S. P. The clinical assessment interview for negative symptoms (CAINS): final development and validation. Am. J. Psychiatry 170, 165\u2013172 (2013).","journal-title":"Am. J. Psychiatry"},{"key":"182_CR34","first-page":"594","volume":"12","author":"D Lukoff","year":"1986","unstructured":"Lukoff, D., Nuechterlein, K. & Ventura, J. Manual for the expanded brief psychiatric rating scale. Schizophrenia Bull. 12, 594\u2013602 (1986).","journal-title":"Schizophrenia Bull."},{"key":"182_CR35","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.schres.2013.12.014","volume":"153","author":"J Addington","year":"2014","unstructured":"Addington, J., Shah, H., Liu, L. & Addington, D. Reliability and validity of the Calgary Depression Scale for Schizophrenia (CDSS) in youth at clinical high risk for psychosis. Schizophrenia Res. 153, 64\u201367 (2014).","journal-title":"Schizophrenia Res."},{"key":"182_CR36","doi-asserted-by":"publisher","first-page":"58","DOI":"10.21500\/20112084.844","volume":"3","author":"D Cousineau","year":"2010","unstructured":"Cousineau, D. & Chartier, S. Outliers detection and treatment: a review. Int. J. Psychol. Res. 3, 58\u201367 (2010).","journal-title":"Int. J. Psychol. Res."}],"container-title":["npj Digital Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41746-019-0182-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-019-0182-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41746-019-0182-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T18:34:25Z","timestamp":1671302065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41746-019-0182-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["182"],"URL":"https:\/\/doi.org\/10.1038\/s41746-019-0182-1","relation":{},"ISSN":["2398-6352"],"issn-type":[{"value":"2398-6352","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,8]]},"assertion":[{"value":"14 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Harvey has received consulting fees or travel reimbursements from Allergan, Alkermes, Akili, Biogen, Boehringer Ingelheim, Forum Pharma, Genentech (Roche Pharma), Intra-Cellular Therapies, Jazz Pharma, Lundbeck Pharma, Minerva Pharma, Otsuka America (Otsuka Digital Health), Sanofi Pharma, Sunovion Pharma, Takeda Pharma, and Teva. He receives royalties from the Brief Assessment of Cognition in Schizophrenia and the MATRICS Consensus Battery. He is chief scientific officer of i-Function, Inc. He has a research grant from Takeda and from the Stanley Medical Research Foundation. Dr. Granholm has received consulting fees from Otsuka Pharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"108"}}